Reported Saturday, Merck's KEYTRUDA Plus Trastuzumab and Chemotherapy Extends Survival In Advanced Gastric Cancer Or GEJ Adenocarcinoma
Portfolio Pulse from Benzinga Newsdesk
Merck's KEYTRUDA, combined with trastuzumab and chemotherapy, shows significant survival benefits in advanced gastric cancer patients, as per the KEYNOTE-811 study. The results were presented at the ESMO Congress 2024 and published in the New England Journal of Medicine.
September 16, 2024 | 6:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA, in combination with trastuzumab and chemotherapy, has shown a significant improvement in overall survival for advanced gastric cancer patients, according to the KEYNOTE-811 study. This could enhance the drug's market position and lead to increased sales.
The positive results from the KEYNOTE-811 study, presented at a major oncology congress and published in a leading medical journal, highlight the efficacy of KEYTRUDA in a new patient population. This could lead to increased adoption and sales, positively impacting Merck's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100